Skip to main content
. 2018 Feb 1;9(16):12805–12811. doi: 10.18632/oncotarget.24375

Table 2. Summary of patients’ information comparing the matched and unmatched subsets against both combined.

Group Patient & Tumor Information
Age Ethnicity Histology Grade Stage Survival (Days) Mortality (%)
All patients (91) 66.1 White: 74;
Black/African American: 8;
Asian: 6;
Hawaiian/Pacific Islander: 2;
Other/Unknown: 1		 Adenocarcinoma, NOS: 50;
Squamous cell carcinoma, NOS: 19;
Non-small cell carcinoma: 9;
Adenosquamous carcinoma: 3;
Papillary adenocarcinoma, NOS: 2;
Squamous cell carcinoma, keratinizing, NOS: 2;
Large cell carcinoma, NOS: 2;
Signet ring cell carcinoma: 1;
Carcinoma, undifferentiated, NOS: 1;
Mucinous adenocarcinoma: 1;
Adenocarcinoma with mixed subtypes: 1		 Grade 3/ Poorly differentiated: 31 (34%);
Grade 2/Moderately differentiated: 31 (34%);
Unknown/Not determined: 13 (14%);
Grade 4/ Undifferentiated: 7 (8%);
Grade 1/Well differentiated: 5 (6%);
None/Not applicable: 4 (4%)		 IV: 43 (47%);
III no IIIC: 25 (28%);
II: 14 (15%);
I: 7 (8%);
Unknown: 2 (2%)		 391 51
Matched only (42) 65.1 White: 34;
Asian: 4;
Black/African American: 2;
Hawaiian/Pacific Islander: 1;
Other/Unknown: 1		 Adenocarcinoma, NOS: 25;
Squamous cell carcinoma, NOS: 7;
Non-small cell carcinoma: 5;
Adenosquamous carcinoma: 1;
Signet ring cell carcinoma: 1;
Papillary adenocarcinoma, NOS: 1;
Adenocarcinoma with mixed subtypes: 1;
Mucinous adenocarcinoma: 1		 Grade 2/Moderately differentiated: 17 (41%);
Grade 3/ Poorly differentiated: 14 (33%);
Unknown/Not determined: 6 (14%);
None/Not applicable: 2 (5%);
Grade 1/Well differentiated: 2 (5%);
Grade 4/ Undifferentiated: 1 (2%)		 IV: 17 (40%);
III no IIIC: 13 (31%);
II: 7 (17%);
I: 4 (10%);
Unknown: 1 (2%)		 402 48
Unmatched (49) 67.1 White: 40;
Black/African American: 6;
Asian: 2;
Hawaiian/Pacific Islander: 1		 Adenocarcinoma, NOS: 25;
Squamous cell carcinoma, NOS: 12;
Non-small cell carcinoma: 4;
Squamous cell carcinoma, keratinizing, NOS: 2;
Adenosquamous carcinoma: 2;
Large cell carcinoma, NOS: 2;
Carcinoma, undifferentiated, NOS: 1;
Papillary adenocarcinoma, NOS: 1		 Grade 3/ Poorly differentiated: 17 (35%);
Grade 2/Moderately differentiated: 14 (29%);
Unknown/Not determined: 7 (14%);
Grade 4/ Undifferentiated: 6 (12%);
Grade 1/Well differentiated: 3 (6%);
None/Not Applicable: 2 (4%)		 IV: 26 (53%);
III no IIIC: 12 (25%);
II: 7 (14%);
I: 3 (6%);
Unknown: 1 (2%)		 382 53